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OBJECTIVE—Because vitamin D deficiency is associated with
a variety of chronic diseases, understanding the characteristics
that promote vitamin D deficiency in otherwise healthy adults
could have important clinical implications. Few studies relating
vitamin D deficiency to obesity have included direct measures of
adiposity. Furthermore, the degree to which vitamin D is asso-
ciated with metabolic traits after adjusting for adiposity mea-
sures is unclear.
RESEARCH DESIGN AND METHODS—We investigated the
relations of serum 25-hydroxyvitamin D (25[OH]D) concentra-
tions with indexes of cardiometabolic risk in 3,890 nondiabetic
individuals; 1,882 had subcutaneous adipose tissue (SAT) and
visceral adipose tissue (VAT) volumes measured by multidetec-
tor computed tomography (CT).
RESULTS—In multivariable-adjusted regression models, 25(OH)D
was inversely associated with winter season, waist circumfer-
ence, and serum insulin (P  0.005 for all). In models further
adjusted for CT measures, 25(OH)D was inversely related to SAT
(1.1 ng/ml per SD increment in SAT, P  0.016) and VAT (2.3
ng/ml per SD, P 0.0001). The association of 25(OH)D with insulin
resistance measures became nonsignificant after adjustment for
VAT. Higher adiposity volumes were correlated with lower
25(OH)D across different categories of BMI, including in lean
individuals (BMI 25 kg/m2). The prevalence of vitamin D defi-
ciency (25[OH]D20 ng/ml) was threefold higher in those with high
SAT and high VAT than in those with low SAT and low VAT (P 
0.0001).
CONCLUSIONS—Vitamin D status is strongly associated with
variation in subcutaneous and especially visceral adiposity. The
mechanisms by which adiposity promotes vitamin D deficiency
warrant further study. Diabetes 59:242–248, 2010
Vitamin D deficiency, as reflected by circulating25-hydroxyvitamin D (25[OH]D) levels less than20 ng/ml, is prevalent in as many as one half ofmiddle-aged to elderly adults in developed coun-
tries (1). In addition to its effects on musculoskeletal
health, a growing body of evidence suggests that individ-
uals with vitamin D deficiency are at increased risk of
cardiovascular morbidity and mortality (2–4). Thus, un-
derstanding the characteristics that promote vitamin D
deficiency in the general population has important clinical
implications.
The major source of vitamin D is endogenous produc-
tion in the skin as a result of sunlight exposure (1).
Notably, one of the clinical characteristics most consis-
tently associated with vitamin D deficiency in prior studies
is obesity (5–9). It is possible that the association between
obesity and vitamin D deficiency is indirect, arising from
obese individuals having less outdoor activity than lean
individuals and, in turn, less sunlight exposure. However,
direct negative effects of obesity on vitamin D status have
also been hypothesized (10–12). Because vitamin D is fat
soluble, vitamin D may be sequestered and stored in fat
tissues (10). Accordingly, experimental and human studies
suggest that greater storage of vitamin D in body fat
decreases the bioavailability of endogenously produced
vitamin D in the circulation (11,12).
Vitamin D deficiency has also been linked to insulin
resistance and the metabolic syndrome (13–15). Previous
studies suggest that the association of vitamin D defi-
ciency with insulin resistance is not attributable entirely to
obesity, although those studies have relied predominantly
on anthropometric measures such as BMI and waist cir-
cumference. Computed tomography (CT) imaging permits
reliable characterization of the subcutaneous and visceral
adipose tissue volumes (16), the latter being the fat
compartment more closely tied to insulin resistance and
metabolic risk (16). Using CT techniques, recent studies in
selected populations suggest that vitamin D may be related
to variation in regional adiposity (17,18).
Therefore, we investigated the cross-sectional relations
of vitamin D status with anthropometric, biochemical, and
imaging measures of adiposity and insulin resistance in a
large, community-based sample. First, we sought to assess
whether serum concentrations of 25(OH)D (the circulating
form that best reflects vitamin D stores) were related to
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measures of adiposity after accounting for physical activ-
ity and dietary vitamin D intake. Second, we assessed
whether 25(OH)D status correlated more closely with
subcutaneous or visceral adipose tissue. Third, we exam-
ined whether serum 25(OH)D was associated with mea-
sures of insulin resistance after accounting for adiposity.
RESEARCH DESIGN AND METHODS
Study sample. The Framingham Heart Study was established in 1948, when
5,209 residents of Framingham, Massachusetts were enrolled in a longitudinal
cohort study designed to prospectively identify risk factors for cardiovascular
disease (19). In 1971, an additional 5,124 participants (offspring of the original
cohort subjects and their spouses) were enrolled in the Framingham Offspring
Study (20). Beginning in 2002, 4,095 Third Generation Study participants, who
had at least one parent in the Offspring cohort, were also enrolled and
underwent standardized clinic examinations at the Heart Study between 2002
and 2005 (21). A total of 3,890 Third Generation participants (96% of
attendees) were free of known cardiovascular disease and diabetes, had a
serum creatinine 1.2 mg/dl, and had measurements of serum 25(OH)D. This
sample (99.5% white and of European ancestry) was used in analyses relating
serum 25(OH)D concentrations with clinical, anthropometric, and biochemi-
cal measures of adiposity and insulin resistance.
Contemporaneous with serum 25(OH)D measurements, a subset of 2,111
Third Generation participants also underwent multidetector CT imaging
between 2002 and 2005. As previously described (16), inclusion in this subset
that underwent imaging was weighted toward participants who resided in the
greater New England area. Participants were eligible if they weighed 350
pounds and were men 35 years of age or women 40 years of age and not
pregnant. Of the participants who underwent CT scans, 1,882 (90%) had
abdominal subcutaneous adipose tissue (SAT) and visceral adipose tissue
(VAT) volumes measured, were free of cardiovascular disease and diabetes,
and had measurement of 25(OH)D. This sample was used for all analyses
relating vitamin D status to regional (i.e., subcutaneous and visceral) adipos-
ity. Individuals who underwent CT imaging were older (45 vs. 35 years), more
likely to be male (57 vs. 43%), and had a slightly higher BMI (27 vs. 26 kg/m2)
than those who did not undergo CT imaging.
The institutional review boards of the Boston University School of Medi-
cine and Massachusetts General Hospital approved the study protocol. All
subjects provided written informed consent.
Clinical assessment. Definitions for standard cardiovascular risk factors
have been detailed previously (22). Physical activity was assessed using a
physical activity index, calculated from the number of hours spent each day at
various activity levels, weighted according to the estimated oxygen consump-
tion required for each activity (23). Data regarding total vitamin D intake from
supplements and diet were obtained using a detailed food-frequency question-
naire (24).
Laboratory assays. Serum samples were obtained in the morning after an
overnight fast and frozen at 80°C. Serum 25(OH)D was determined by
radioimmunoassay (DiaSorin, Stillwater, MN). The intraassay coefficient of
variation was 12.5%. For the present analysis, vitamin D deficiency was
defined as having a 25(OH)D concentration 20 ng/ml (1). Plasma insulin and
proinsulin were measured by separate ELISA procedures (Millipore Bio-
science, Billerica, MA), each of which had negligible cross-reactivity with
other insulin-like molecules. The intraassay coefficients of variation for these
assays were 2.7 and 2.4%, respectively. The homeostasis model assessment of
insulin resistance (HOMA-IR) was assessed from fasting insulin and glucose
levels, (25) where individuals with values in the top quartile were considered
to have elevated HOMA-IR.
Abdominal adipose tissue imaging and measurements. Imaging was
performed with an 8-slice multidetector CT scanner (Lightspeed Ultra; Gen-
eral Electric, Milwaukee, WI) using a standard protocol that has been reported
previously (26). Briefly, 25 contiguous 5-mm-thick slices were acquired above
the level of S1. The abdominal muscular wall separating visceral from
subcutaneous fat compartments was manually traced on acquired images and
volumetric assessments were made. Intrareader and interreader reproducibil-
ity was high, with interclass correlations of 0.997 for SAT and 0.992 for VAT
(18). High and low values for VAT and SAT measures were defined as being
above or below 90th percentile sex-specific cutoffs for men and women from
a healthy reference sample (27).
Statistical analyses. Continuous variables with skewed distributions were
logarithmically transformed (triglycerides, vitamin D intake, insulin, and
proinsulin). Multivariable linear regression was performed in the total sample
to examine the association of 25(OH)D (dependent variable) with the follow-
ing clinical, anthropometric, and metabolic variables (independent variables):
age, sex, cigarette smoking, log triglycerides, HDL cholesterol, systolic blood
pressure, antihypertensive treatment, BMI, waist circumference, physical
activity index, log dietary vitamin D intake, fasting glucose, log insulin, log
proinsulin, HOMA-IR (75th percentile), and the metabolic syndrome (pres-
ence of 3 of the following: waist circumference 40 inches in men or 35
inches in women; serum triglycerides 150 mg/dl or taking medication for
hypertriglyceridemia [fibrates or niacin derivatives]; HDL cholesterol 40
mg/dl in men or 50 mg/dl in women or taking medication for reduced HDL
cholesterol [fibrates or niacin derivatives]; systolic blood pressure 130
mmHg or diastolic blood pressure 85 mmHg or taking antihypertensive
medication; and fasting glucose 100 mg/dl) (28). The association of each
variable with 25(OH)D was initially examined with adjustment for age, sex,
and winter season (January through April) (29,30). We then conducted
multivariable regression analyses with stepwise forward selection to evaluate
the independent association of 25(OH)D with each of the clinical, anthropo-
metric, and metabolic variables listed above. A P value 0.10 was the
significance criterion for covariates to enter and remain in the regression
model.
For the subset of individuals who underwent multidetector CT, clinical and
metabolic covariates that were significant in the stepwise model were entered
into a multivariable regression model along with SAT and VAT, incorporating
the latter two separately and conjointly. To assess whether SAT or VAT was
more strongly associated with 25(OH)D, we performed a bootstrap analysis to
compare the standardized regression coefficients for SAT and VAT (31).
Specifically, 10,000 random samples with replacement were taken from the
original sample, and two multivariable linear regressions (one with SAT and
one with VAT) were run on each sample. An overall estimate of the SAT and
VAT regression coefficients, their variances, and their covariance were then
estimated using the bootstrap approach on the 10,000 samples, and a Z test for
the difference in regression coefficients was calculated. Anthropometric
variables (BMI or waist circumference) were included in models with VAT but
not in models with SAT, to avoid collinearity between SAT and anthropomet-
ric indexes (16). In all models that examined the relations of 25(OH)D with
SAT or VAT, we included additional covariates known to correlate with CT
measures of adiposity, that is, hormone replacement therapy (in women),
menopausal state (in women), and alcohol use (32). To assess the relation of
insulin resistance with 25(OH)D after accounting for different measures of
adiposity, we entered each of four surrogate markers of insulin resistance
(fasting glucose, log insulin, HOMA-IR, log proinsulin) as a separate additional
covariate into multivariable models that adjusted for one of the following
adiposity measures: BMI, waist circumference, SAT, or VAT.
In secondary analyses, we repeated the analyses using generalized estimat-
ing equations to account for correlations among related individuals (siblings)
in the study sample (PROC GENMOD; SAS Institute, Cary, NC) (33). To
examine adiposity and body size separately, we repeated multivariable
analyses of adiposity measures within subgroups defined by BMI category
(25, 25 to 30, and 30 kg/m2).
All analyses were performed using SAS Version 9.1.3 (SAS Institute), and a
two-tailed P value of 0.05 was considered statistically significant.
RESULTS
The characteristics of the study sample are shown in Table
1. The mean age was 40 years, and 54% of participants
were women. Overall, 22% of participants were obese
(BMI 30 kg/m2) and 35% were overweight (BMI 25
kg/m2 and 30 kg/m2).
The age-, sex-, and season-adjusted associations of
25(OH)D with clinical and metabolic traits are shown in
Table 2. 25(OH)D was positively related to dietary vitamin
D intake (P  0.0001) and physical activity (P  0.0001).
Significant inverse associations were noted between
25(OH)D and each of the remaining clinical and metabolic
covariates, including measures of insulin resistance. After
adjusting for age, sex, and season, the presence of meta-
bolic syndrome was associated with lower 25(OH)D con-
centration (4.5 ng/ml, P  0.0001).
Multivariable analyses. Results of the stepwise multiva-
riable regression model are shown in Table 3. Higher
25(OH)D was associated with nonwinter season, smaller
waist circumference, increased physical activity, and
greater vitamin D intake. After adjustment for these co-
variates, 25(OH)D was also inversely associated with
serum insulin levels (P  0.004).
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In the subgroup of individuals who had CT measures of
regional adiposity, multivariable analyses were performed
relating 25(OH)D to regional adiposity adjusting for the
clinical and metabolic covariates derived from the afore-
mentioned stepwise regression model. When SAT and VAT
were entered separately into these models, 25(OH)D was
inversely associated with each of these adiposity measures
(P  0.0001 for both VAT and SAT). These relations were
significant when SAT and VAT were treated as either
continuous or categorical measures (Table 4). When fur-
ther adjustment for waist circumference was made, the
association of 25(OH)D with VAT remained statistically
significant. Notably, after inclusion of VAT in multivariable
models, the association of 25(OH)D with both waist cir-
cumference (P 0.183) and HOMA-IR (P 0.394) became
nonsignificant. In bootstrap analyses, the multivariable-
adjusted regression coefficient for a standard deviation
increment in VAT was significantly greater than that for
the same increment in SAT (P  0.009). When both SAT
and VAT were entered into a single model, as shown in
Table 4, each of these measures remained inversely asso-
ciated with 25(OH)D (P  0.016 for SAT, P  0.0001 for
VAT).
The multivariable-adjusted relations of 25(OH)D with
several markers of insulin resistance, including fasting
glucose, serum insulin, and HOMA-IR, remained signifi-
cant in models adjusting for BMI or waist circumference.
These relations were moderately attenuated in models
adjusting for SAT and nonsignificant in models adjusting
for VAT (Table 5). 25(OH)D was not associated with serum
proinsulin in multivariable models adjusting for any mea-
sure of obesity.
Results were similar when the analyses were repeated
using generalized estimating equations. In analyses within
BMI subgroups, the association of 25(OH)D with regional
adiposity was more consistent for VAT than SAT (Table 6).
The multivariable-adjusted association of 25(OH)D with
SAT was significant in overweight and obese people, but
not in lean people. On the other hand, the association of
25(OH)D with VAT was significant in all BMI subgroups.
TABLE 1
Study sample characteristics
Whole sample
(n  3,890)
Clinical and anthropometric measures
Age (years) 40.0 8.7
Women 54
Winter season 30
BMI (kg/m2) 26.7 5.3
Waist circumference (cm) 99.5 14.7
Systolic blood pressure (mmHg) 116 14
Diastolic blood pressure (mmHg) 75 10
Hypertension 17
Smoker 17
Physical activity index 37.5 7.8
Postmenopausal 6
Hormone replacement therapy 3
Alcohol use* 15
Vitamin D intake (IU) 378 290
Metabolic syndrome 19
Biochemical measures
25(OH)D (ng/ml) 37.2 14.5
HDL cholesterol (mg/dl) 54.7 16.1
Triglycerides (mg/dl) 91.0 (64–135)
Fasting plasma glucose (mg/dl) 93.1 8.5
Impaired fasting glucose† 5
Insulin (pmol/l) 25.2 (18.7–36.5)
HOMA-IR† 0.8 (0.6–1.2)
Proinsulin (pmol/l) 5.9 (4.1–9.3)
CT measures‡
SAT (cm3) 2,754.8  1,397.0
VAT (cm3) 1,568.5 893.3
Data are means  SD (for continuous variables that are normally
distributed), median (interquartile range) (for continuous variables
that are not normally distributed), or percent. *Defined as 14
drinks/week (men) or 7 drinks/week (women). †Fasting plasma
glucose 100–125 mg/dl. ‡Data from the sample subset (n  1,882)
with CT-based adiposity measures available.
TABLE 2
Age-, sex-, and season-adjusted relations of individual clinical
and metabolic covariates and serum 25(OH)D (n  3,890)
Coefficient (SE)* P
Age 0.71 (0.22) 0.001
Female sex 2.50 (0.44) 0.0001
Winter season 9.53 (0.48) 0.0001
Smoker 1.22 (0.59) 0.037
Log triglycerides 1.48 (0.23) 0.0001
HDL cholesterol 1.51 (0.25) 0.0001
Systolic blood pressure 1.66 (0.24) 0.0001
Antihypertensive treatment 1.22 (0.79) 0.125
BMI 2.81 (0.23) 0.0001
Waist circumference 3.11 (0.24) 0.0001
Physical activity index 1.30 (0.22) 0.0001
Log vitamin D intake 2.34 (0.23) 0.0001
Fasting glucose 3.63 (0.53) 0.0001
Log insulin 2.29 (0.24) 0.0001
HOMA-IR 4.31 (0.54) 0.0001
Log proinsulin 1.96 (0.25) 0.0001
SAT† 2.65 (0.31) 0.0001
VAT† 3.58 (0.36) 0.0001
*Coefficients represent change in 25(OH)D (ng/ml) for an increase in
the value of the predictor variables shown (1-SD increase for
continuous predictor variables). The coefficient change for age, sex,
and season are each adjusted for the other two covariates. †Data are
from the sample subset (n  1,882) with CT-based adiposity mea-
sures available.
TABLE 3
Stepwise multivariable-adjusted relations of clinical and meta-
bolic covariates with 25(OH)D in the absence of SAT or VAT as
potential covariates
Coefficient (SE)* P
Female sex 0.91 (0.53) 0.084
Winter season 9.08 (0.52) 0.0001
Systolic blood pressure 0.48 (0.27) 0.080
Waist circumference 2.42 (0.33) 0.0001
Physical activity index 1.08 (0.25) 0.0001
Log vitamin D intake 2.16 (0.24) 0.0001
Log insulin 0.87 (0.30) 0.004
*Coefficients represent change in 25(OH)D (ng/ml) for an increase in
the value of the predictor variables shown (1-SD increase for
continuous predictor variables). The stepwise multivariable model
adjusted for the following variables: age, sex, season, smoker, log
triglycerides, HDL cholesterol, systolic blood pressure, antihyperten-
sive treatment, BMI, waist circumference, physical activity, log
vitamin D intake, fasting glucose, log insulin, log proinsulin, and
HOMA-IR. Variables that were entered into but did not remain
significant in this stepwise forward regression model included age,
smoker, log triglycerides, HDL cholesterol, antihypertensive treat-
ment, BMI, fasting glucose, log proinsulin, and HOMA-IR.
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Prevalence of vitamin D deficiency. Overall, vitamin D
deficiency (20 ng/ml) was more frequent among individ-
uals with high SAT compared with those with low SAT
(13.7 vs. 6.7%, P  0.0001) and in individuals with high
compared with low VAT (15.4 vs. 5.7%, P  0.0001). The
prevalence of vitamin D deficiency rose with increasing
VAT tertile, even among lean individuals (Fig. 1). Individ-
uals with both high SAT and high VAT had an approxi-
mately threefold prevalence of vitamin D deficiency
compared with those with both low SAT and low VAT
(15.8 vs. 5.1%, P  0.001; Fig. 2).
DISCUSSION
Principal findings. The principal findings of our study are
threefold. First, we observed a relation of lower vitamin D
concentrations with greater BMI that was not explained by
variation in physical activity or vitamin D intake. Second,
we found an inverse relation of 25(OH)D with subcutane-
ous and especially visceral adiposity, even among lean
individuals, underscoring the specific importance of adi-
pose tissue, above and beyond body size, as a correlate of
vitamin D status. Third, associations between 25(OH)D
and commonly used markers of insulin resistance were
markedly attenuated when accounting for variations in
regional and particularly visceral adiposity.
Vitamin D and obesity. Prior studies have described an
association between vitamin D deficiency and obesity, but
residual confounding could exist from factors such as
limited physical activity (7,9) or low vitamin D intake
(7–9,34). One of the advantages of our cohort was that
participants were generally young to middle-aged, with
few comorbidities, and very low rates of medication use.
Furthermore, information on physical activity level and
vitamin D intake from diet and supplements was routinely
ascertained. We observed a robust association between
25(OH)D and anthropometric measures even after taking
into account these potential confounders.
A limitation of anthropometric measures is that they do
not distinguish fat from lean mass. A few studies have
reported an inverse correlation between vitamin D and
total body fat, assessed using skin-fold measures or dual-
energy X-ray absorptiometry, (35–37) but these methods
TABLE 4
Multivariable-adjusted relations of adiposity measures with 25(OH)D
Model 1* Model 2 Model 3
Regression
coefficient (SE)† P
Regression
coefficient (SE) P
Regression
coefficient (SE) P
Continuous variables
SAT 2.02 (0.41) 0.0001 — 1.12 (0.47) 0.016
VAT — 3.00 (0.51) 0.0001 2.34 (0.58) 0.0001
Categorical variables‡
High SAT (vs. low SAT) 2.94 (0.83) 0.0004 — 2.22 (0.86) 0.010
High VAT (vs. low VAT) — 3.32 (0.86) 0.0001 2.67 (0.90) 0.003
*In models 1 and 2, SAT and VAT are entered separately while adjusting for sex, season, systolic blood pressure, physical activity, log vitamin
D intake, and log insulin. In model 3, both SAT and VAT are entered in the model while adjusting for the same aforementioned covariates.
†Coefficients represent change in 25(OH)D (ng/ml) for an increase in the value of the predictor variables shown (1-SD increase for continuous
predictor variables). ‡High SAT and VAT were defined as values 90th sex-specific percentile, as derived from a healthy reference sample.
TABLE 5
Multivariable-adjusted relations of 25(OH)D with insulin resis-
tance measures
Regression
coefficient (SE)* P
Model adjusting for standard
covariates plus BMI
Fasting glucose 1.14 (0.57) 0.047
Log insulin 0.90 (0.30) 0.003
HOMA-IR 1.62 (0.62) 0.009
Log proinsulin 0.24 (0.31) 0.445
Model adjusting for standard
covariates plus waist
circumference
Fasting glucose 0.95 (0.57) 0.099
Log insulin 0.82 (0.30) 0.006
HOMA-IR 1.54 (0.62) 0.014
Log proinsulin 0.17 (0.31) 0.586
Model adjusting for standard
covariates plus SAT
Fasting glucose 1.68 (0.80) 0.036
Log insulin 0.93 (0.41) 0.024
HOMA-IR 1.54 (0.84) 0.066
Log proinsulin 0.58 (0.40) 0.152
Model adjusting for standard
covariates plus VAT
Fasting glucose 1.13 (0.82) 0.166
Log insulin 0.50 (0.43) 0.245
HOMA-IR 0.75 (0.86) 0.383
Log proinsulin 0.07 (0.43) 0.874
*Coefficients represent change in 25(OH)D (ng/ml) for an increase in
the value of the predictor variables shown (1-SD increase for
continuous predictor variables). All models include adjustment for
the following standard covariates: sex, winter season, systolic blood
pressure, physical activity index, and log vitamin D intake.
TABLE 6
Multivariable-adjusted relations of adiposity measures with
25(OH)D by BMI
BMI category
SAT VAT
Regression
coefficient
(SE)* P
Regression
coefficient
(SE) P
Lean: 25 kg/m2 0.68 (1.53) 0.656 3.30 (1.59) 0.038
Overweight: 25 to
30 kg/m2 2.39 (1.15) 0.039 2.78 (0.89) 0.002
Obese: 30 kg/m2 1.64 (0.71) 0.023 2.11 (0.90) 0.019
*Coefficients represent change in 25(OH)D (ng/ml) for an increase in
the value of the predictor variables shown (1-SD increase for
continuous predictor variables). Relations of adiposity measures
with 25(OH)D are adjusted for sex, season, systolic blood pressure,
physical activity, vitamin D intake, and log insulin.
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are unable to characterize the type and distribution of fat
deposits. On the other hand, CT imaging allows for a
detailed, volumetric quantification of the subcutaneous
and visceral abdominal adipose tissue compartments. Re-
cent studies have reported an association of 25(OH)D with
regional adiposity assessed by CT in nonwhite individuals
(17) and in obese adolescents (18). Our data extend these
findings to a larger, predominantly white cohort, uns-
elected on the basis of BMI or vitamin D status. The size of
the cohort enabled subgroup analyses within strata of
BMI, as well as multivariable models incorporating a range
of clinical and biochemical variables.
Although SAT and VAT are highly correlated with each
other, (16) they appeared independently associated with
25(OH)D. This observation suggests that subcutaneous
and visceral fat depots are each separately related to
vitamin D status. Interestingly, the association of VAT with
25(OH)D was also present within categories of BMI, even
among individuals with low BMI. In contrast, the associa-
tion of SAT with 25(OH)D was attenuated in the lowest
BMI subgroup. Because SAT and BMI are closely corre-
lated, it is possible that most of the association between
SAT and 25(OH)D is attributable to variation in body size
that is also captured by BMI.
Vitamin D deficiency may be related to adiposity via
several mechanisms. Some have theorized that obesity is
associated with decreased sunlight exposure, from less
outdoor activity or clothing habits that limit cutaneous
vitamin D synthesis. As noted above, however, the associ-
ation between 25(OH)D and adipose tissue volumes was
unchanged by adjustment for physical activity and was
present even in analyses restricted to lean individuals.
Furthermore, experimental studies indicate that differ-
ences in sunlight exposure are not enough to account for
the differences in vitamin D concentrations seen between
obese and nonobese volunteers (12). Thus, confounding
by differences in sunlight exposure is highly unlikely as an
explanation for poorer vitamin D status with greater
adiposity.
Because vitamin D is fat soluble, many investigators
have proposed that the sequestration of vitamin D metab-
olites in fat compartments decreases their bioavailability
in obese compared with nonobese people (12). According
to this hypothesis, variation in serum 25(OH)D, the storage
form of vitamin D, should correlate closely with variation
in measures of SAT, which is by far the body’s largest
volume depot of fat. Although SAT was indeed associated
with 25(OH)D, we observed an even stronger relation of
25(OH)D with VAT.
There are some experimental data to suggest that vitamin
D deficiency could promote greater adiposity. Moderate to
severe vitamin D deficiency leads to elevated parathyroid
hormone, which may promote calcium influx into adipocytes
and thereby enhance lipogenesis (38). Moreover, accumulat-
ing evidence suggests that 1,25-hydroxyvitamin D modulates
adipogenesis through vitamin D receptor–dependent inhibi-
tion of critical molecular components of adipogenesis such
as peroxisome proliferator–activated receptor  and C/EBP
(39). Therefore, depletion of vitamin D stores may lead to
excess differentiation of preadipocytes to adipocytes.
Taken together, our findings suggest that multiple mech-
anisms could potentially contribute to the robust associa-
tion of vitamin D with adiposity. Although 25(OH)D was
more strongly related to VAT than SAT, having greater
adiposity in both visceral and subcutaneous compart-
ments appeared to have an additive relation to vitamin D
status. Indeed, being in the highest compared with lowest
category of total abdominal fat volume (SAT and VAT
together) was associated with a threefold higher rate of
vitamin D deficiency.
Vitamin D, visceral adiposity, and insulin resistance.
As with prior studies, we observed that vitamin D defi-
ciency was associated with insulin resistance and related
traits (40–42). It has been proposed that vitamin D defi-
ciency directly promotes insulin resistance, although prior
data are conflicting (15). Experimental studies indicate
that vitamin D has the ability to stimulate pancreatic
insulin secretion (43–45). However, results of studies
examining the effects of vitamin D administration on
insulin secretion in humans have been mixed (46–48).
Interestingly, although the association between 25(OH)D
and insulin resistance measures persisted with adjustment
for BMI and waist circumference, it became attenuated
after adjustment for SAT and nonsignificant after adjust-
ment for VAT. This observation raises the possibility that
the relation between vitamin D deficiency and metabolic
traits (10,34,49) could be explained, in large part, by its
association with adiposity, particularly in the visceral
compartment. Although both subcutaneous and visceral
fat depots are metabolically active (22), VAT is considered
the more pathogenic compartment and is more often
associated with secretion of adipokines, mediators of
hemostasis and fibrinolysis, and growth factors (16). Fur-
thermore, VAT is more strongly correlated than SAT with
cardiovascular risk factors such as hypertension, hypertri-
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glyceridemia, impaired fasting glucose, and the metabolic
syndrome (16,27,50).
Limitations and strengths. Several limitations of this
study merit consideration. We did not have specific infor-
mation on sun exposure or time spent outdoors. Thus,
both season and the physical activity index were used as
surrogates for solar radiation, which directly influences
cutaneous vitamin D production. The use of cross-
sectional data precludes inference of a causal relation
between regional adiposity and vitamin D deficiency. It
remains possible that specific patterns of adiposity pro-
mote vitamin D deficiency, that depletion of vitamin D
stores contributes to specific patterns of adiposity, or that
both are the product of another primary process. Further
research is needed to explore these potential relations.
The results of our study may not be generalizable to all
racial/ethnic groups or age groups given that our sample
was primarily white and young to middle-aged. Multivari-
able analyses were unable to adjust for parathyroid hor-
mone because this was not measured in our sample.
Furthermore, adiposity measures were performed on only
a subset of the population. We did not subdivide subcuta-
neous fat into superficial and deep compartments, and so
we cannot comment on the relative importance of these
subcompartments with respect to variation in vitamin D
concentrations. Also, we measured only abdominal and
not truncal or limb SAT (35).
Notwithstanding the above limitations, the present
study had several strengths, including the use of a com-
munity-based sample not selected on the basis of adipos-
ity-related traits, cardiovascular disease risk factors, or
vitamin D status. We used a highly reproducible volumet-
ric method of assessing SAT and VAT, which accounts for
heterogeneity of fat distribution throughout the abdomen.
Lastly, our large sample size provided adequate power to
perform multivariable analyses and compare strengths of
association.
Clinical implications. We observed that lower 25(OH)D
was associated with greater regional adiposity, a finding
that was not attributable to differences in physical activity
or vitamin D intake. The association between 25(OH)D
and adiposity was stronger for visceral than subcutaneous
abdominal adiposity, and significant across the spectrum
of body size. In fact, the relation of 25(OH)D with adipos-
ity was present even among healthy, lean individuals who
might otherwise not be considered at risk for vitamin D
deficiency. Furthermore, relations of 25(OH)D with insulin
resistance markers were markedly attenuated by adjust-
ment for visceral adiposity, suggesting that excess visceral
adiposity could contribute to the observed relationship of
vitamin D with insulin resistance and the metabolic
syndrome.
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